Table 3.
Coronary heart disease event rates by genetic risk and treatment allocation
| Trial / Polygenic risk score subgroup | Placebo
|
Statin Treated
|
ARR (%) | NNT | ||||
|---|---|---|---|---|---|---|---|---|
| Events (n) | Individuals (n) | Event rate (%) | Events (n) | Individuals (n) | Event rate (%) | |||
| WOSCOPS (604 events, 8.1 years of follow-up) | ||||||||
| All Others | 248 | 1,929 | 12.9% | 201 | 1,981 | 10.1% | 2.7% | 38 |
| High | 100 | 511 | 19.6% | 55 | 471 | 11.7% | 7.9% | 13 |
| JUPITER (108 events, 2.4 years of follow-up) | ||||||||
| All Others | 53 | 3,486 | 1.5% | 35 | 3,483 | 1.0% | 0.5% | 200 |
| High | 14 | 864 | 1.6% | 6 | 878 | 0.7% | 0.9% | 112 |
| ASCOT-LLA (149 events, 6.1 years of follow-up) | ||||||||
| All Others | 61 | 1,619 | 3.8% | 45 | 1,756 | 2.6% | 1.2% | 84 |
| High | 28 | 426 | 6.6% | 15 | 418 | 3.6% | 3.0% | 34 |
ARR = absolute risk reduction; NNT = number needed to treat with statin to prevent one event.
JUPITER and ASCOT-LLA data from Mega J*, Stitziel NO*, et al. Lancet. 20155 *Denotes equal contribution